These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 26597368)

  • 1. Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases.
    Hughes MS; Zager J; Faries M; Alexander HR; Royal RE; Wood B; Choi J; McCluskey K; Whitman E; Agarwala S; Siskin G; Nutting C; Toomey MA; Webb C; Beresnev T; Pingpank JF
    Ann Surg Oncol; 2016 Apr; 23(4):1309-19. PubMed ID: 26597368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience.
    Forster MR; Rashid OM; Perez MC; Choi J; Chaudhry T; Zager JS
    J Surg Oncol; 2014 Apr; 109(5):434-9. PubMed ID: 24249545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemosaturation with percutaneous hepatic perfusion for unresectable isolated hepatic metastases from sarcoma.
    Deneve JL; Choi J; Gonzalez RJ; Conley AP; Stewart S; Han D; Werner P; Chaudhry TA; Zager JS
    Cardiovasc Intervent Radiol; 2012 Dec; 35(6):1480-7. PubMed ID: 22699779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study.
    Meijer TS; Burgmans MC; de Leede EM; de Geus-Oei LF; Boekestijn B; Handgraaf HJM; Hilling DE; Lutjeboer J; Vuijk J; Martini CH; van Erkel AR; van der Meer RW; Tijl FGJ; Speetjens FM; Kapiteijn E; Vahrmeijer AL
    Ann Surg Oncol; 2021 Feb; 28(2):1130-1141. PubMed ID: 32761328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Embolization of variant hepatic arteries in patients undergoing percutaneous hepatic perfusion for unresectable liver metastases from ocular melanoma.
    Meijer TS; Geus-Oei LF; Martini CH; Tijl FGJ; Sitsen ME; Erkel ARV; Meer RWV; Kapiteijn E; Vahrmeijer AL; Burgmans MC
    Diagn Interv Radiol; 2019 Nov; 25(6):451-458. PubMed ID: 31650973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems' Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial.
    Meijer TS; Burgmans MC; Fiocco M; de Geus-Oei LF; Kapiteijn E; de Leede EM; Martini CH; van der Meer RW; Tijl FGJ; Vahrmeijer AL
    Cardiovasc Intervent Radiol; 2019 Jun; 42(6):841-852. PubMed ID: 30767147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease.
    Karydis I; Gangi A; Wheater MJ; Choi J; Wilson I; Thomas K; Pearce N; Takhar A; Gupta S; Hardman D; Sileno S; Stedman B; Zager JS; Ottensmeier C
    J Surg Oncol; 2018 May; 117(6):1170-1178. PubMed ID: 29284076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic artery infusion of melphalan in patients with liver metastases from ocular melanoma.
    Boone BA; Perkins S; Bandi R; Santos E; McCluskey K; Bartlett DL; Pingpank JF
    J Surg Oncol; 2018 Apr; 117(5):940-946. PubMed ID: 29878390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver.
    Alexander HR; Libutti SK; Bartlett DL; Puhlmann M; Fraker DL; Bachenheimer LC
    Clin Cancer Res; 2000 Aug; 6(8):3062-70. PubMed ID: 10955785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery.
    Dewald CLA; Becker LS; Maschke SK; Meine TC; Alten TA; Kirstein MM; Vogel A; Wacker FK; Meyer BC; Hinrichs JB
    Clin Exp Metastasis; 2020 Dec; 37(6):683-692. PubMed ID: 33034815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review.
    Vogel A; Gupta S; Zeile M; von Haken R; Brüning R; Lotz G; Vahrmeijer A; Vogl T; Wacker F
    Adv Ther; 2017 Jan; 33(12):2122-2138. PubMed ID: 27798773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic Progression-free and Overall Survival After Regional Therapy to the Liver for Metastatic Melanoma.
    Abbott AM; Doepker MP; Kim Y; Perez MC; Gandle C; Thomas KL; Choi J; Shridhar R; Zager JS
    Am J Clin Oncol; 2018 Aug; 41(8):747-753. PubMed ID: 28059929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases.
    Carr MJ; Sun J; Cohen JB; Liu J; Serdiuk AA; Stewart SR; Doobay N; Duclos A; Seal DA; Choi J; Zager JS
    Cancer Control; 2020; 27(1):1073274820983019. PubMed ID: 33372814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of partial venovenous cardiopulmonary bypass in percutaneous hepatic perfusion for patients with diffuse, isolated liver metastases: a case series.
    Fitzpatrick M; Richard Alexander H; Deshpande SP; Martz DG; McCormick B; Grigore AM
    J Cardiothorac Vasc Anesth; 2014 Jun; 28(3):647-51. PubMed ID: 24290749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma.
    Modi S; Gibson T; Vigneswaran G; Patel S; Wheater M; Karydis I; Gupta S; Takhar A; Pearce N; Ottensmeier C; Stedman B
    Melanoma Res; 2022 Apr; 32(2):103-111. PubMed ID: 35254333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival.
    Marquardt S; Kirstein MM; Brüning R; Zeile M; Ferrucci PF; Prevoo W; Radeleff B; Trillaud H; Tselikas L; Vicente E; Wiggermann P; Manns MP; Vogel A; Wacker FK
    Eur Radiol; 2019 Apr; 29(4):1882-1892. PubMed ID: 30255257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options.
    Agarwala SS; Eggermont AM; O'Day S; Zager JS
    Cancer; 2014 Mar; 120(6):781-9. PubMed ID: 24301420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience.
    Artzner C; Mossakowski O; Hefferman G; Grosse U; Hoffmann R; Forschner A; Eigentler T; Syha R; Grözinger G
    Cancer Imaging; 2019 May; 19(1):31. PubMed ID: 31146793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers.
    Vogl TJ; Zangos S; Scholtz JE; Schmitt F; Paetzold S; Trojan J; Orsi F; Lotz G; Ferrucci P
    Rofo; 2014 Oct; 186(10):937-44. PubMed ID: 24729409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis.
    Tong TML; Samim M; Kapiteijn E; Meijer TS; Speetjens FM; Brüning R; Schroeder TH; El-Sanosy S; Maschke H; Wacker FK; Vogel A; Dewald CLA; Goeman JJ; Burgmans MC
    Cardiovasc Intervent Radiol; 2022 Sep; 45(9):1304-1313. PubMed ID: 35922562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.